Friday, 16 October 2026European Markets

FONCIERE VOLTA And NEXTENSA Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - fonciere volta (spel.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
fonciere volta (spel.pa) €7.50 6.51% 1.81%
nextensa (nexta.br) €44.90 5.83% 6.98%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. fonciere volta (spel.pa)

6.51% forward dividend yield and 1.81% return on equity

foncière volta acquires, constructs, holds, and rents real estate properties in france and internationally. its portfolio consists of apartment buildings, offices, and commercial premises, such as warehouses, retail stores, and hotel properties. the company was incorporated in 1986 and is headquartered in paris, france.

earnings per share

as for profitability, fonciere volta has a trailing twelve months eps of €-1.02.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.81%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, fonciere volta's stock is considered to be oversold (<=20).

moving average

fonciere volta's value is below its 50-day moving average of €7.80 and under its 200-day moving average of €7.91.

revenue growth

year-on-year quarterly revenue growth declined by 82.1%, now sitting on 9.98m for the twelve trailing months.

dividend yield

as stated by morningstar, inc., the next dividend payment is on sep 22, 2022, the estimated forward annual dividend rate is 0.54 and the estimated forward annual dividend yield is 6.51%.

more news about fonciere volta.

2. nextensa (nexta.br)

5.83% forward dividend yield and 6.98% return on equity

nextensa is a mixed-use real estate investor and developer. the company's investment portfolio is divided between the grand duchy of luxembourg (44%), belgium (41%) and austria (15%); its total value as of 30/09/2023 was approximately €1.29 billion. as a developer, nextensa is primarily active in shaping large urban developments. at tour & taxis (development of over 350,000 sqm) in brussels, nextensa is building a mixed real estate portfolio consisting of a revaluation of iconic buildings and new constructions. in luxembourg (cloche d'or), it is working in partnership on a major urban extension of more than 400,000 sqm consisting of offices, retail and residential buildings. the company is listed on euronext brussels and has a market capitalization of €457.1 million (value 30/09/2023).

earnings per share

as for profitability, nextensa has a trailing twelve months eps of €5.76.

pe ratio

nextensa has a trailing twelve months price to earnings ratio of 7.8. meaning, the purchaser of the share is investing €7.8 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.98%.

more news about nextensa.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com